Clinical Trial Update: Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating RiMO-301 with radiotherapy and a PD-1 inhibitor for head and neck cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• PD-1 inhibitor
• RiMO-301

Snippet

Sponsor: Coordination Pharmaceuticals, Inc. | Conditions: Head Neck Cancer, Intratumoral Injection | Phase 1, Phase 2 | Status: RECRUITING